Nouscom Strengthens its Management Team
26th February 2020 – Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer Nouscom, an immuno-oncology company developing [...]
26th February 2020 – Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer Nouscom, an immuno-oncology company developing [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
